Takahiro Imaizumi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Takahiro Imaizumi has a total of 356 co-authors. Here are the top co-authors by number of shared publications:
- Shoichi Maruyama
Department of Nephrology Nagoya University Graduate School of Medicine Nagoya Japan
15 shared publications - Masaki Okazaki
Department of Nephrology, Nagoya University Graduate School of Medicine , Nagoya
8 shared publications - Shimon Kurasawa
Department of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan
8 shared publications - Nobuhiro Nishibori
Department of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan
7 shared publications Shoichi Maruyama
Department of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan
7 shared publicationsManabu Hishida
Department of Nephrology, Kaikoukai Josai Hospital, Nagoya, Japan
6 shared publications
Latest Publications
- Open Access
- 2 November 2026
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 19 (11)
Hypocalcaemia and hospitalization after initiation of bone-modifying agents in dialysis patients
Background and hypothesis: Bone-modifying agents are associated with hypocalcaemia in dialysis patients, leading to serious adverse consequences. We examined factors associated with all-cause hospitalization, longitudinal serum calcium trajectories by medication class, and baseline predictors of hypocalcaemia in dialysis patients initiating bone-modifying agents. Methods: Using the JMDC hospital database, we identified dialysis patients newly prescribed bisphosphonates, denosumab, teriparatide, or romosozumab. Factors associated with all-cause hospitalization were examined using Cox regression. Serum calcium trajectories were assessed over 90 days before and after treatment initiation. Factors associated with hypocalcaemia (corrected calcium <8.0 mg/dl) within 90 days were analysed. Results: Among 2020 patients on dialysis, 1057 (52.3%) received bisphosphonates; 693 (34.3%), denosumab; 136 (6.7%), teriparatide; and 134 (6.6%), romosozumab. Hospitalization occurred in 425 patients, and recent hospitalization and pretreatment lower corrected serum calcium levels were associated with hospitalization, with no significant differences across medications. Among 374 patients with laboratory data, post-treatment hypocalcaemia occurred in 99 (26.5%). Persistent reductions in serum calcium levels were observed after initiating denosumab or romosozumab. Adjusted odds ratios (OR) for post-treatment hypocalcaemia were 13.4 (6.90–26.1) for denosumab and 8.09 (2.20–29.8) for romosozumab. Pretreatment calcium and parathyroid hormone levels were associated with post-treatment hypocalcaemia [adjusted ORs: 0.29 (0.18, 0.49) and 1.59 (1.05, 2.39), respectively]. Conclusion: In dialysis patients, denosumab and romosozumab were associated with a higher risk of post-treatment hypocalcaemia than bisphosphonates, and pretreatment lower calcium was associated with hospitalization. Our findings highlight the importance of optimizing parathyroid hormone management and enhancing calcium monitoring when initiating bone-modifying agents.
- 2 November 2026
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 19 (11)
Open AccessHypocalcaemia and hospitalization after initiation of bone-modifying agents in dialysis patients
Background and hypothesis: Bone-modifying agents are associated with hypocalcaemia in dialysis patients, leading to serious adverse consequences. We examined factors associated with all-cause hospitalization, longitudinal serum calcium trajectories by medication class, and baseline predictors of hypocalcaemia in dialysis patients initiating bone-modifying agents. Methods: Using the JMDC hospital database, we identified dialysis patients newly prescribed bisphosphonates, denosumab, teriparatide, or romosozumab. Factors associated with all-cause hospitalization were examined using Cox regression. Serum calcium trajectories were assessed over 90 days before and after treatment initiation. Factors associated with hypocalcaemia (corrected calcium <8.0 mg/dl) within 90 days were analysed. Results: Among 2020 patients on dialysis, 1057 (52.3%) received bisphosphonates; 693 (34.3%), denosumab; 136 (6.7%), teriparatide; and 134 (6.6%), romosozumab. Hospitalization occurred in 425 patients, and recent hospitalization and pretreatment lower corrected serum calcium levels were associated with hospitalization, with no significant differences across medications. Among 374 patients with laboratory data, post-treatment hypocalcaemia occurred in 99 (26.5%). Persistent reductions in serum calcium levels were observed after initiating denosumab or romosozumab. Adjusted odds ratios (OR) for post-treatment hypocalcaemia were 13.4 (6.90–26.1) for denosumab and 8.09 (2.20–29.8) for romosozumab. Pretreatment calcium and parathyroid hormone levels were associated with post-treatment hypocalcaemia [adjusted ORs: 0.29 (0.18, 0.49) and 1.59 (1.05, 2.39), respectively]. Conclusion: In dialysis patients, denosumab and romosozumab were associated with a higher risk of post-treatment hypocalcaemia than bisphosphonates, and pretreatment lower calcium was associated with hospitalization. Our findings highlight the importance of optimizing parathyroid hormone management and enhancing calcium monitoring when initiating bone-modifying agents.
- 19 September 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Quality of Care and Clinical Outcomes
Care gaps following newly detected dipstick proteinuria in treated hypertension: a Japanese nationwide database study
Aims: Clinical guidelines recommend follow-up quantitative testing after dipstick-positive proteinuria and, when proteinuria is confirmed, subsequent initiation of renin–angiotensin system inhibitors (RASi) in patients with hypertension. However, real-world adherence to these recommendations remains unclear. We investigated management patterns following newly detected dipstick proteinuria in patients with treated hypertension. Methods and results: Using the JMDC claims database, we identified treated hypertensive patients with newly detected dipstick proteinuria (≥1+, with prior results <1+) between January 2005 and March 2025. The study outcomes were quantitative urine albumin/protein testing and RASi initiation. Cumulative incidence was estimated using the Kaplan–Meier method, and multivariable Cox models were used to identify factors associated with outcomes. The 365-day cumulative incidence of quantitative testing was 7.5% [95% confidence interval (CI): 7.2–7.7] in the overall population (n = 47 210), and that of RASi initiation was 13.2% (95% CI: 12.6–13.8) among baseline RASi non-users (n = 14 599). Both outcomes became more frequent with increasing dipstick grade but remained infrequent in the higher-grade groups: among patients with 2+ and 3+ proteinuria, quantitative testing was performed in 12.9 and 16.1%, respectively, and RASi initiation occurred in 17.5 and 21.7%, respectively. Temporal trend analysis indicated that RASi initiation rates showed no improvement (adjusted hazard ratio [aHR] per year: 1.01; 95% CI: 0.99–1.03). Conclusion: Follow-up quantitative testing and RASi initiation after newly detected dipstick proteinuria were infrequent, even among patients with higher dipstick grades, and RASi initiation showed no clear improvement over time. These findings highlight opportunities to improve guideline-concordant urinary protein assessment and antihypertensive therapy.
- 19 September 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Quality of Care and Clinical Outcomes
Care gaps following newly detected dipstick proteinuria in treated hypertension: a Japanese nationwide database study
Aims: Clinical guidelines recommend follow-up quantitative testing after dipstick-positive proteinuria and, when proteinuria is confirmed, subsequent initiation of renin–angiotensin system inhibitors (RASi) in patients with hypertension. However, real-world adherence to these recommendations remains unclear. We investigated management patterns following newly detected dipstick proteinuria in patients with treated hypertension. Methods and results: Using the JMDC claims database, we identified treated hypertensive patients with newly detected dipstick proteinuria (≥1+, with prior results <1+) between January 2005 and March 2025. The study outcomes were quantitative urine albumin/protein testing and RASi initiation. Cumulative incidence was estimated using the Kaplan–Meier method, and multivariable Cox models were used to identify factors associated with outcomes. The 365-day cumulative incidence of quantitative testing was 7.5% [95% confidence interval (CI): 7.2–7.7] in the overall population (n = 47 210), and that of RASi initiation was 13.2% (95% CI: 12.6–13.8) among baseline RASi non-users (n = 14 599). Both outcomes became more frequent with increasing dipstick grade but remained infrequent in the higher-grade groups: among patients with 2+ and 3+ proteinuria, quantitative testing was performed in 12.9 and 16.1%, respectively, and RASi initiation occurred in 17.5 and 21.7%, respectively. Temporal trend analysis indicated that RASi initiation rates showed no improvement (adjusted hazard ratio [aHR] per year: 1.01; 95% CI: 0.99–1.03). Conclusion: Follow-up quantitative testing and RASi initiation after newly detected dipstick proteinuria were infrequent, even among patients with higher dipstick grades, and RASi initiation showed no clear improvement over time. These findings highlight opportunities to improve guideline-concordant urinary protein assessment and antihypertensive therapy.
- Open Access
- 19 September 2026
- Published by Springer Nature in Clinical and Experimental Nephrology
- p. 1-10
Associations between erythropoietin resistance and iron metabolism markers in patients undergoing extended-hours and conventional hemodialysis
Background: Extended-hours hemodialysis, defined as ≥6 h/session, three or four times per week, has been associated with lower erythropoietin resistance index (ERI), although the biological mechanisms remain unclear. We aimed to compare the associations between ERI and iron metabolism markers in patients undergoing extended-hours versus conventional hemodialysis. Methods: We included patients who received either extended-hours or conventional hemodialysis between January and March 2020. The ERI was calculated by dividing the weekly erythropoiesis-stimulating agent (ESA) dose, expressed as epoetin equivalents divided by body weight and hemoglobin level. Linear and non-linear associations were evaluated using multivariable linear regression and restricted cubic spline (RCS) analyses. Results: We analyzed 366 patients (178 receiving extended-hours hemodialysis and 188 receiving conventional hemodialysis). Hemoglobin levels were 10.9 and 11.2 g/dL, median ferritin levels were 34.8 and 63.6 ng/mL, and median transferrin saturation (TSAT) values were 16.9% and 20.5%, respectively. Extended-hours hemodialysis was associated with a lower ERI after multivariable adjustment (coefficient, −4.49 IU/kg/week per g/dL; 95% confidence interval, −6.76 to −2.22). In the RCS analysis, ERI increased with decreasing ferritin levels in the conventional hemodialysis group, whereas no increase was observed at lower ferritin levels in the extended-hours group. A similar trend was observed with respect to TSAT. Conclusions: Extended-hours hemodialysis was associated with lower ERI. Exploratory RCS analyses suggested potential modality-related differences in the relationships between ERI and ferritin or TSAT. These findings suggest that the association between iron status and ESA responsiveness may differ by dialysis modality and warrants further investigation.
- 19 September 2026
- Published by Springer Nature in Clinical and Experimental Nephrology
- p. 1-10
Open AccessAssociations between erythropoietin resistance and iron metabolism markers in patients undergoing extended-hours and conventional hemodialysis
Background: Extended-hours hemodialysis, defined as ≥6 h/session, three or four times per week, has been associated with lower erythropoietin resistance index (ERI), although the biological mechanisms remain unclear. We aimed to compare the associations between ERI and iron metabolism markers in patients undergoing extended-hours versus conventional hemodialysis. Methods: We included patients who received either extended-hours or conventional hemodialysis between January and March 2020. The ERI was calculated by dividing the weekly erythropoiesis-stimulating agent (ESA) dose, expressed as epoetin equivalents divided by body weight and hemoglobin level. Linear and non-linear associations were evaluated using multivariable linear regression and restricted cubic spline (RCS) analyses. Results: We analyzed 366 patients (178 receiving extended-hours hemodialysis and 188 receiving conventional hemodialysis). Hemoglobin levels were 10.9 and 11.2 g/dL, median ferritin levels were 34.8 and 63.6 ng/mL, and median transferrin saturation (TSAT) values were 16.9% and 20.5%, respectively. Extended-hours hemodialysis was associated with a lower ERI after multivariable adjustment (coefficient, −4.49 IU/kg/week per g/dL; 95% confidence interval, −6.76 to −2.22). In the RCS analysis, ERI increased with decreasing ferritin levels in the conventional hemodialysis group, whereas no increase was observed at lower ferritin levels in the extended-hours group. A similar trend was observed with respect to TSAT. Conclusions: Extended-hours hemodialysis was associated with lower ERI. Exploratory RCS analyses suggested potential modality-related differences in the relationships between ERI and ferritin or TSAT. These findings suggest that the association between iron status and ESA responsiveness may differ by dialysis modality and warrants further investigation.
- Open Access
- 17 August 2026
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 2 (5)
Nationwide TREC/KREC-based newborn screening and clinical outcomes in Japan
Large-scale real-world data on T-cell receptor excision circle (TREC)– and κ-deleting recombination excision circle (KREC)–based newborn screening for inborn errors of immunity remain limited. In this nationwide cohort, we evaluated Japan’s program (2020–2025), including 1,380,634 newborns. Of 869 referred infants (0.06%), 40 were diagnosed, including 15 with severe combined immunodeficiency (SCID), 16 with X-linked agammaglobulinemia or other agammaglobulinemias, and nine with severe T cell lymphopenia. After a median follow-up of 18 mo, overall survival was 98%. All infants with SCID survived; 14 underwent hematopoietic cell transplantation with sustained engraftment. Referral rates were 0.04% for TREC and 0.03% for KREC. Repeat sampling was associated with lower referral rates (0.05 vs. 0.56%). Referral rates varied across assay kits and laboratory practices, reflecting interlaboratory heterogeneity in a decentralized screening system. The transition from self-paid to public funding increased coverage from 77.1 to 97.7%. These findings support TREC/KREC-based screening and highlight the need for standardized algorithms and sustained public funding for equitable nationwide implementation.
- 17 August 2026
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 2 (5)
Open AccessNationwide TREC/KREC-based newborn screening and clinical outcomes in Japan
Large-scale real-world data on T-cell receptor excision circle (TREC)– and κ-deleting recombination excision circle (KREC)–based newborn screening for inborn errors of immunity remain limited. In this nationwide cohort, we evaluated Japan’s program (2020–2025), including 1,380,634 newborns. Of 869 referred infants (0.06%), 40 were diagnosed, including 15 with severe combined immunodeficiency (SCID), 16 with X-linked agammaglobulinemia or other agammaglobulinemias, and nine with severe T cell lymphopenia. After a median follow-up of 18 mo, overall survival was 98%. All infants with SCID survived; 14 underwent hematopoietic cell transplantation with sustained engraftment. Referral rates were 0.04% for TREC and 0.03% for KREC. Repeat sampling was associated with lower referral rates (0.05 vs. 0.56%). Referral rates varied across assay kits and laboratory practices, reflecting interlaboratory heterogeneity in a decentralized screening system. The transition from self-paid to public funding increased coverage from 77.1 to 97.7%. These findings support TREC/KREC-based screening and highlight the need for standardized algorithms and sustained public funding for equitable nationwide implementation.
- 5 May 2026
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 20 (7) , 1367-1376
Multidimensional lipid phenotyping for stratification of residual cardiovascular risk: A focus on fatty acid balance
- 5 May 2026
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 20 (7) , 1367-1376
Multidimensional lipid phenotyping for stratification of residual cardiovascular risk: A focus on fatty acid balance
- Open Access
- 3 April 2026
- Published by Springer Nature in Clinical and Experimental Nephrology
- Vol. 30 (6) , 856-865
Evidence–practice gaps in chronic kidney disease management among patients taking antidiabetic or antihypertensive medications: a nationwide analysis of Japanese primary care electronic health records
Background: The management of chronic kidney disease (CKD) in primary care remains poorly defined despite primary care physicians managing a high proportion of patients with hypertension and diabetes. This study examined CKD-related laboratory testing and anemia management patterns in Japanese primary care settings. Methods: Using the Japan Medical Data Survey (JAMDAS) database, we analyzed electronic health records from Japanese primary care clinics. We included patients aged ≥ 18 years who received antihypertensive or antidiabetic medications at least twice in 2024 and visited clinics quarterly, excluding those who received kidney replacement therapy. Results: Among 859,044 eligible patients (mean age: 70.3 years; men: 48.9%), estimated glomerular filtration rate, dipstick proteinuria, serum potassium, and hemoglobin were measured in 76.2%, 11.2%, 62.9%, and 69.6% of patients, respectively. Proteinuria testing declined with increasing age. Of 604,936 patients who underwent any anemia-related laboratory testing, only 5.1%, 0.4%, and 15.1% had their serum ferritin, transferrin saturation, and serum iron measured, respectively. Among 5219 patients with coded renal anemia, 73.9% received erythropoiesis-stimulating agents (ESAs) or hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs). Notably, 58.6% of 553 patients with a renal anemia diagnosis and hemoglobin levels ≥ 13 g/dL were treated with ESAs or HIF-PHIs. Conclusion: Evidence–practice gaps in CKD management were identified in Japanese primary care settings, including limited proteinuria testing and raising hemoglobin levels above guideline-recommended limits, despite inadequate evaluation of iron parameters. These findings indicate that systematic quality improvement initiatives are needed to improve CKD management in primary care.
- 3 April 2026
- Published by Springer Nature in Clinical and Experimental Nephrology
- Vol. 30 (6) , 856-865
Open AccessEvidence–practice gaps in chronic kidney disease management among patients taking antidiabetic or antihypertensive medications: a nationwide analysis of Japanese primary care electronic health records
Background: The management of chronic kidney disease (CKD) in primary care remains poorly defined despite primary care physicians managing a high proportion of patients with hypertension and diabetes. This study examined CKD-related laboratory testing and anemia management patterns in Japanese primary care settings. Methods: Using the Japan Medical Data Survey (JAMDAS) database, we analyzed electronic health records from Japanese primary care clinics. We included patients aged ≥ 18 years who received antihypertensive or antidiabetic medications at least twice in 2024 and visited clinics quarterly, excluding those who received kidney replacement therapy. Results: Among 859,044 eligible patients (mean age: 70.3 years; men: 48.9%), estimated glomerular filtration rate, dipstick proteinuria, serum potassium, and hemoglobin were measured in 76.2%, 11.2%, 62.9%, and 69.6% of patients, respectively. Proteinuria testing declined with increasing age. Of 604,936 patients who underwent any anemia-related laboratory testing, only 5.1%, 0.4%, and 15.1% had their serum ferritin, transferrin saturation, and serum iron measured, respectively. Among 5219 patients with coded renal anemia, 73.9% received erythropoiesis-stimulating agents (ESAs) or hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs). Notably, 58.6% of 553 patients with a renal anemia diagnosis and hemoglobin levels ≥ 13 g/dL were treated with ESAs or HIF-PHIs. Conclusion: Evidence–practice gaps in CKD management were identified in Japanese primary care settings, including limited proteinuria testing and raising hemoglobin levels above guideline-recommended limits, despite inadequate evaluation of iron parameters. These findings indicate that systematic quality improvement initiatives are needed to improve CKD management in primary care.
- Open Access
- 15 December 2025
- Published by Elsevier in Kidney Medicine
- Vol. 8 (2)
Growth Failure Associated With Parathyroid Hormone Levels in Pediatric Dialysis Patients: A Nationwide Cohort Study
- 15 December 2025
- Published by Elsevier in Kidney Medicine
- Vol. 8 (2)
Open AccessGrowth Failure Associated With Parathyroid Hormone Levels in Pediatric Dialysis Patients: A Nationwide Cohort Study
- Open Access
- 18 November 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 40427
Risk factors of adverse pregnancy outcomes in patients with immunoglobulin A nephropathy
Pregnancy and childbirth are major concerns for women with immunoglobulin A nephropathy (IgAN), because it peaks in their child-bearing age. To provide evidence for optimal pre-conception care, we investigated whether the disease control status, assessed by blood pressure and/or urine protein level, is associated with adverse pregnancy outcomes. This case–control study used data from 924,238 patients with chronic kidney disease obtained from a hospital claims database. We included 297 pregnancies with IgAN and collected data on antihypertensive medications and glucocorticoid therapy within six months before conception as the exposures. The outcomes were hypertensive disorders of pregnancy (HDP) that required intravenous nicardipine and preterm delivery. We estimated the adjusted odds ratios (aORs) using multivariable logistic regression. The prescriptions of antihypertensive medications other than renin–angiotensin–aldosterone system inhibitors (RASi) were significantly associated with both severe HDP requiring intravenous nicardipine (aOR: 5.01, 95% confidence interval [CI]: 1.43–17.5) and preterm delivery (aOR: 6.45, 95% CI: 1.81–23.0), compared with those of only RASi. No significant associations were observed between glucocorticoid therapy and outcomes. Regarding pre-conception care, our findings suggest that pre-conception antihypertensive medication use, as a surrogate marker for underlying hypertension, may help identify women with IgAN at higher risk of adverse pregnancy outcomes.
- 18 November 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 40427
Open AccessRisk factors of adverse pregnancy outcomes in patients with immunoglobulin A nephropathy
Pregnancy and childbirth are major concerns for women with immunoglobulin A nephropathy (IgAN), because it peaks in their child-bearing age. To provide evidence for optimal pre-conception care, we investigated whether the disease control status, assessed by blood pressure and/or urine protein level, is associated with adverse pregnancy outcomes. This case–control study used data from 924,238 patients with chronic kidney disease obtained from a hospital claims database. We included 297 pregnancies with IgAN and collected data on antihypertensive medications and glucocorticoid therapy within six months before conception as the exposures. The outcomes were hypertensive disorders of pregnancy (HDP) that required intravenous nicardipine and preterm delivery. We estimated the adjusted odds ratios (aORs) using multivariable logistic regression. The prescriptions of antihypertensive medications other than renin–angiotensin–aldosterone system inhibitors (RASi) were significantly associated with both severe HDP requiring intravenous nicardipine (aOR: 5.01, 95% confidence interval [CI]: 1.43–17.5) and preterm delivery (aOR: 6.45, 95% CI: 1.81–23.0), compared with those of only RASi. No significant associations were observed between glucocorticoid therapy and outcomes. Regarding pre-conception care, our findings suggest that pre-conception antihypertensive medication use, as a surrogate marker for underlying hypertension, may help identify women with IgAN at higher risk of adverse pregnancy outcomes.